These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Clinical effect of ampicillin with beta-lactamase inhibitor (sulbactam/ampicillin) on community-acquired pneumonia in the elderly.
    Author: Okimoto N, Kurihara T, Honda N, Asaoka N, Fujita K, Ohba H, Nakamura J.
    Journal: J Infect Chemother; 2003 Jun; 9(2):183-6. PubMed ID: 12825120.
    Abstract:
    Sulbactam/ampicillin (SBT/ABPC) was administered to 83 patients aged over 75 years with community-acquired bacterial pneumonia (mild, n = 43; moderate, n = 40), and its clinical effect was reviewed. It was effective in 37 of the 43 patients with mild disease (efficacy rate, 86.0%), in 27 of the 40 patients with moderate disease (efficacy rate, 67.5%), and overall in 64 of the 83 patients (efficacy rate, 77.1%). Side effects included drug eruption in 1 patient (1.2%) and abnormal laboratory findings in 11 (13.3%), all of which were mild. Based on the above, SBT/ABPC may be recommended as the first-choice drug for community-acquired bacterial pneumonia in the elderly.
    [Abstract] [Full Text] [Related] [New Search]